Modus Therapeutics Holding AB (publ) (STO:MODTX)

Market Cap	69.00M
Revenue (ttm)	n/a
Net Income (ttm)	-15.26M
Shares Out	35.94M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,594
Average Volume	51,972
Open	1.785
Previous Close	1.790
Day's Range	1.725 - 2.050
52-Week Range	1.120 - 3.600
Beta	0.38
RSI	63.25
Earnings Date	Aug 7, 2025

About Chimerix

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 2
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MODTX